Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS Divests Indonesian OTC Business, Continues Biopharma Consolidation

This article was originally published in The Tan Sheet

Executive Summary

Japanese firm Taisho Pharmaceutical will acquire nearly all shares of Bristol-Myers Squibb's Asian OTC subsidiary

You may also be interested in...



Reckitt Deals Feed OTC Domination Plan

Reckitt Benckiser CEO Rakesh Kapoor plays up the firm’s potential to dominate the fragmented global consumer health product market and says Reckitt is better positioned than big pharma firms to manage OTC businesses. Reckitt continued its emerging markets focus with OTC deals in Latin America and China.

Reckitt Deals Feed OTC Domination Plan

Reckitt Benckiser CEO Rakesh Kapoor plays up the firm’s potential to dominate the fragmented global consumer health product market and says Reckitt is better positioned than big pharma firms to manage OTC businesses. Reckitt continued its emerging markets focus with OTC deals in Latin America and China.

Bristol-Myers Squibb To Sell Australian Manufacturing Facility To Generics Maker Sigma

PERTH, Australia - Bristol-Myers Squibb revealed Sept. 7 that it plans to sell its Australian manufacturing facility in Melbourne to generic drug maker Sigma Pharmaceuticals for roughly AU$60 million. The Melbourne-based plant is the only production facility held by BMS in Australia

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel